Home > Topic > Science

SCIENCE

Doctors attend to a COVID-19 patient at the Government Institute of Medical Sciences, in Greater Noida, Uttar Pradesh. (PTI)

CSIR-Laxai receive DCGI nod to begin trials for Colchicine in Covid patients

1 min read . Updated: 12 Jun 2021

Govt launches job portal for placing workers in MSMEs. 5 things to know

Govt launches job portal for placing workers in MSMEs. 5 things to know

1 min read . Updated: 11 Feb 2021

Shares of Jubilant Life Sciences closed at ₹719 per scrip on BSE (MINT_PRINT)

Jubilant Life Sciences raises ₹90 crore through commercial papers

1 min read . Updated: 26 Nov 2020

Shares of Jubilant Life Sciences closed at ₹706.70 per scrip on BSE (MINT_PRINT)

Jubilant Life Sciences Q2 result: Profit declines 10% to ₹224 crore

1 min read . Updated: 04 Nov 2020

Photo: Bloomberg

Nearly 1 lakh data science jobs vacant in India: Study

2 min read . Updated: 07 Oct 2020

Remdesivir is an experimental antiviral drug developed by Gilead Sciences as a course of treatment for the novel coronavirus (REUTERS)

Covid-19: India and Pakistan ramp up remdesivir production, says report

1 min read . Updated: 21 Sep 2020

Gilead’s $20 billion gamble

2 min read . Updated: 14 Sep 2020

‘Really diabolical’: Inside the coronavirus that outsmarted science

14 min read . Updated: 08 Sep 2020

In this file photo one vial of the drug Remdesivir lies during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany (AFP)

Remdesivir has marginal benefit for moderate COVID-19 patients: Gilead study

1 min read . Updated: 21 Aug 2020

India Life Sciences Fund III, which has a corpus of $250 million, provides growth capital to pharma, healthcare, animal hea-lth and medtech businesses.

India Life Sciences Fund invests ₹100 cr in Inventia Healthcare

1 min read . Updated: 18 Aug 2020

(Photo: Reuters)

Jubilant Life Sciences launches remdesivir for injection at ₹4,700 per vial

1 min read . Updated: 03 Aug 2020

A scientist doing the tests pertaining to the research (REUTERS)

Scientists identify the key enzyme behind body odour

1 min read . Updated: 27 Jul 2020

A healthcare worker takes samples to test elderly residents for the new coronavirus at the San Jose nursing home in Cochabamba, Bolivia, Friday, July 17, 2020. (Photo: AP) (AP)

Older adults coped with COVID-19 pandemic best, UBC study reveals

1 min read . Updated: 23 Jul 2020

Gilead donated remdesivir to hospitals through June, but the company announced at the close of that month its plans to charge $390 a vial, or $2,340 for a five-day regimen, for direct government purchases by the U.S. or other developed countries. (REUTERS)

Pharma firms boost lobbying in race for coronavirus treatment, vaccine

3 min read . Updated: 21 Jul 2020

Gilead begins testing inhalable form of remdesivir for COVID-19

1 min read . Updated: 09 Jul 2020

The University of Chicago is one of 152 locations participating in Gilead's trial involving severe COVID-19 patients (AP)

Covid-19: Gilead Sciences to start trials of inhaled version of remdesivir Aug

2 min read . Updated: 23 Jun 2020

Several organisations have organised lectures on the eclipse and also the virtual viewing of the phenomenon.

Solar eclipse timings today: Parts of India to see full annular solar eclipse

2 min read . Updated: 21 Jun 2020

The healthcare-focused PE fund is in advanced stages of closing two more pharma deals, collectively worth ₹250 crore. (Photo: Bloomberg)

India Life Sciences Fund invests ₹140 cr in 2 firms

1 min read . Updated: 17 Jun 2020

Companies around the wold have been working hard to develop a cure--a vaccine/drug--to treat covid-19. (AP Photo/Sakchai Lalit)

Dr Reddy’s, Syngene among four more firms in pact with Gilead for remdesivir

1 min read . Updated: 13 Jun 2020

×

Get alerts on WhatsApp

Set Preferences My Reads Feedback Redeem a Gift Card Logout